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ORIGINAL CLINICAL STUDY
Purpose: To evaluate the efficacy and safety of early pars plana 
vitrectomy (PPV) for the treatment of acute infective endophthalmitis, 
and identify prognostic factors for better visual outcome.
Design: Retrospective cohort study. 
Methods: Consecutive patients who underwent early PPV within 
72 hours of presentation for the treatment of acute infective bacterial 
endophthalmitis and presented to a large tertiary referral center in New 
South Wales, Australia, between January 2009 and December 2013 were 
included. Changes in best-corrected visual acuity (VA) from baseline to 
1 year were examined. 
Results: A total of 64 patients were included. The inciting events were 
cataract surgery (53%), intravitreal injection (36%), trabeculectomy 
(3%), and endogenous (3%). The mean VA improved from 3.1 logMAR 
(hand motion) at baseline to 1.02 (approximately 20/200) at 1 year, with 
42% achieving final VA equal to or better than 0.477 logMAR (20/60) 
following early PPV. Positive prognostic factors were negative microbial 
cultures (P < 0.01) and etiology of post–cataract surgery (P < 0.01). In 
multivariable analyses adjusting for age and prognostic factors, patients 
with baseline VA of light perception and hand motion achieved greater 
visual gains than those with counting fingers, with gains of logMAR of 
−2.68, −2.09, and −0.85, respectively (P < 0.0001). 
Conclusion: Most patients who undergo early PPV experience 
substantial VA improvement. Negative microbial cultures and 
endophthalmitis after cataract surgery were associated with better final 
visual outcome. Patients with presenting VA of light perception or hand 
motion achieved higher visual gains than those with counting fingers, 
suggesting the possibility that early PPV may be beneficial in both groups.
Key Words: cataract surgery, early vitrectomy, endophthalmitis, 
intravitreal injection, visual acuity
(Asia Pac J Ophthalmol (Phila) 2019;8:3–7)
Acute-onset infectious endophthalmitis (IE) remains one of the most challenging and devastating complications in 
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ophthalmic surgery. It is defined as severe inflammation of the 
ocular tissues and fluids resulting from either direct inoculation 
of a pathogen from surgery or trauma, or from the hematogenous 
spread of organisms from a distant source.1 
Since 1995, management of acute-onset IE has been based 
predominantly on findings of the Endophthalmitis Vitrectomy 
Study (EVS).1 This prospective randomized trial found no benefit 
from immediate pars plana vitrectomy (PPV) when compared 
with vitreous tap and intravitreal injection of antibiotics in patients 
with IE after cataract surgery, except in the subgroup where visual 
acuity (VA) at presentation was light perception (LP) or worse. 
More recently, there have been suggestions that PPV should be 
performed earlier and in patients with better than LP vision.2–5 
It is thought that early vitrectomy may be beneficial as it allows 
for the debridement of bacteria, inflammatory cells, and other 
toxic debris from the vitreous cavity; promotes better diffusion 
of antibiotics; removes inflammatory membranes and provides 
earlier visualisation of the retina.1 Significant advancements 
in vitreoretinal surgery technology have occurred since the 
EVS was published.6,7 This has allowed surgeons to perform a 
more thorough vitrectomy while reducing the risk of inducing 
iatrogenic retinal injury and subsequent retinal detachment. 
Moreover, the patient population presenting with acute 
IE postoperatively is evolving with the increasing number of 
cases due to intravitreal injections.5,8–11 The direct inoculation 
of infectious pathogens into the vitreous cavity and the higher 
frequency of Streptococcus spp associated with this patient 
population makes it different from IE after cataract extraction.12–14 
These factors point to the need for more data on early PPV for 
acute IE to guide the optimal management of contemporary 
patients.
The purpose of this study was to evaluate the efficacy 
and safety of micro-incisional early PPV for the treatment and 
management of patients presenting with acute-onset IE. We also 
aimed to identify prognostic factors for better visual outcome in 
this patient population. 
METHODS
We performed a retrospective cohort study of 64 consecutive 
patients who underwent early PPV within 72 hours of presentation 
for the treatment of acute-onset IE. The charts of all patients who 
presented to the Sydney Eye Hospital, a tertiary referral center 
for the state of New South Wales, Australia, with suspected 
acute-onset IE and underwent early PPV between January 2009 
and December 2013 were reviewed. Inclusion criteria were a 
clinical diagnosis of microbial endophthalmitis confirmed by a 
vitreoretinal specialist, documented anterior-chamber hypopyon 
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and fibrin, loss of red reflex, and vitreous opacities present on 
B-scan ultrasound. All cases had a minimum of 12 months’ follow-
up after the initial surgery. Approval was obtained from the South 
East Sydney Local Health District Human Ethics Review Board 
for this study. Because this retrospective study was carried out 
using patient data in an anonymous manner, the requirement for 
written informed consent from individual patients was waived. 
Data collected from clinical records included: age; sex; 
ocular history; cause of endophthalmitis; number of days from 
inciting event to presentation; number of days from presentation 
to undergoing PPV; Snellen best-corrected VA at presentation and 
1, 3, 6, and 12 months postoperatively, as well as at the last follow-
up visit. The presenting symptoms and findings, intraoperative 
techniques, culture results, complications (retinal detachment, 
epiretinal membrane, ocular hypotony or hypertension, phthisis, 
and evisceration), and length of follow-up were also documented. 
Visual acuities were converted to logMAR values, as per the 
description by Ferris et al.15 A logMAR of +4.0, +3.0, and +2.0 
was assigned to VA of LP, hand motion (HM), and counting 
fingers (CF) vision, respectively, according to the methods 
published by Holladay.16 
The indication for early PPV in this study was poor vision 
(CF or worse) at presentation. All patients in this study underwent 
a standard pars plana vitreous tap and injection protocol at 
presentation prior to undergoing PPV. An initial preparation with a 
drop of anesthetic (0.5% tetracaine) and povidone-iodine solution 
was applied to the affected eye. Subconjunctival lidocaine (2%) 
was injected near the anticipated site of intravitreal injection. 
Sterile preparation of eyelashes and eyelids with povidone-
iodine was performed. A 0.2-mL vitreous sample was taken for 
microbiological assessment followed by intravitreal injection of 
1 mg of vancomycin in 0.1-mL solution and 2.25 mg of 
ceftazidime in 0.1-mL solution. 
All patients subsequently underwent standard 23-gauge 
3-port PPV within 72 hours of presentation. Anterior chamber 
washout was performed in all patients. A core vitrectomy was 
undertaken and the amount of vitreous removed was directly 
related to quality of the surgical view. When required, the corneal 
epithelium was debrided. If a retinal break or retinal detachment 
was seen intraoperatively, endolaser and/or cryoretinopexy 
was applied to the affected area. Silicone oil was used as an 
endotamponade agent in all cases when retinal detachment was 
present intraoperatively. In the remaining cases, a partial fluid-air 
exchange followed by intravitreal injection of 1 mg of vancomycin 
and 2.25 mg of ceftazidime was performed. Postoperatively, all 
patients were treated with topical antibiotics and steroids as well 
as oral ciprofloxacin.
The primary outcome of this study was final VA at 1 year. 
The secondary outcomes were adverse events associated with 
surgical intervention as well as prognostic factors associated with 
improvement in final VA.
Statistical Analysis
We compared categorical variables using Fisher exact 
test, and continuous variables using the paired samples t test. 
Multivariable mixed models were constructed using variables 
that were associated with improvement in final VA in univariable 
analyses. All analyses were performed with SAS software, 
version 9.4 (SAS Institute, Cary, NC, US). A P value of <0.05 
was considered statistically significant. 
RESULTS
A total of 64 eyes of 64 patients (36 women and 28 men) met 
the inclusion criteria during the 5-year study period. The median 
age was 77.5 years (range, 43–92 years) at the time of surgery 
(Table 1). The inciting factor for IE was phacoemulsification 
and intraocular lens implant in 34 patients (53%), intravitreal 
injections in 23 patients (36%), trabeculectomy surgery in 
2 patients (3%), endogenous source in 2 patients (3%), and the 
remaining 3 (5%) followed a vitrectomy, an intraocular lens 
exchange, and a globe rupture (Table 1). Of 23 patients secondary 
to intravitreal injections, 19 (83%) were post ranibizumab, 2 (9%) 
post triamcinolone, 1 (4%) post bevacizumab, and 1 (4%) post 
aflibercept. The mean time of onset from the inciting factor, 
excluding the 2 endogenous cases, was 5.7 days. The interval 
between injection and subsequent vitrectomy was within 72 hours. 
The mean time from antibiotic injection to undergoing vitrectomy 
was 0.8 days. The decision was based on clinical evidence of 
worsening. The 2 patients who developed endophthalmitis after 
intravitreal triamcinolone had culture-positive vitreous taps, 
which grew Staphylococcus epidermidis and Staphylococcus 
aureus. Of the 42 (66%) culture-positive samples, 43% grew 
S. epidermidis; 33% grew Streptococcus spp; 12% grew S. 
aureus; 5% grew Enterococcus spp; and 2% grew Haemophilus, 
Klebsiella, and Moraxella spp (Table 1).
Table 2 summarizes the mean VA endpoints for all patients 
TABLE 1. Baseline Characteristics of Patients with Endophthalmitis (n 
= 64)
No. (%) of Patients*
Demographics
Age, y
Mean ± SD 74.8 ± 11.4









Intravitreal injection 23 (36)
Other 7 (11)
Time of onset (excluding endogenous), d
Mean ± SD 5.7 ± 9.5
Median; range 4; 2–77
Time from injection to vitrectomy, d
Mean ± SD 0.8 ± 1.2
Median; range 0 (same day); 0–3
Culture positive 42 (66)
Gram-positive 39 (93)
Staphylococcus epidermidis 18 (43)
Staphylococcus aureus 5 (12)
Enterococcus spp 2 (5)
Streptococcus spp 14 (33)
Gram-negative 3 (7)
*Unless otherwise stated.
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as well as the subgroups of patients based on culture results, type 
of microorganism, as well as inciting factor at presentation, 1 
month, 3 months, 6 months, and 1 year (mean follow-up, 21.9 
weeks). Considering all patients enrolled, the presenting mean 
VA was logMAR of +3.1 which improved to +1.02 at 1 year 
(P < 0.001). Presenting VA was worse for patients who were 
culture positive than culture negative (logMAR, +3.26 vs +2.79; 
P = 0.03), but similar for cataract surgery and intravitreal injection 
patients (logMAR, +3.06 vs +3.07, P = 0.96). Most patients 
experienced substantial improvement in VA, with 57 patients 
(89%) improved by 1 line or greater.
Univariate and multivariate analyses were performed to 
identify predictive factors for improvement in VA (Table 3). The 
group with the highest proportion of patients with VA equal to 
or better than +0.3 logMAR were those with culture-negative 
results (45% of patients), compared with 14% of patients with 
culture-positive results. Of those that were gram-positive, only 
patients who grew S. epidermidis had a VA equal to or better than 
+0.3 logMAR (33%, P = 0.04); patients with other gram-positive 
organisms had poorer outcomes. 
Table 3 also shows that patients who developed IE after 
cataract surgery had better outcomes compared with those who 
had intravitreal injections. At 1-year post diagnosis, 35% of 
patients who had cataract surgery had a VA equal to or less than 
+0.3 logMAR compared with 13% of patients who had intravitreal 
injections, although the difference was not statistically significant 
TABLE 2. Changes in Visual Acuity After Early Vitrectomy from Baseline to 1 Year








Months P value* At 1 Year P value*
All patients 3.1 (3) 1.44 (1) 1.08 (1) 1.02 (0.89) 1.02 (0.89) <0.001
Culture-positive 3.26 0.03 1.66 0.02 1.32 0.005 1.26 0.003 1.22 0.01
Culture-negative 2.79 0.99 0.64 (4) 0.58 0.65
Gram-positive 3.31 (3) 0.11 1.59 (1.3) 0.08 1.28 (1) 0.27 1.21 (1) 0.22 1.18 (1) 0.19
Gram-negative 2.67 (3) 2.67 (3) 2 (2) 2 (2) 2 (2)
Staphylococcus epidermidis 3.11 (3) 0.18 1.30 (1) 0.34 0.99 (0.54) 0.17 0.88 (0.48) 0.11 0.86 (0.48) 0.11
Staphylococcus aureus 3.6 (4) 1.98 (2) 1.77 (2) 1.77 (2) 1.74 (2)
Streptococcus spp 3.36 (3.5) 1.84 (2) 1.53 (1.3) 1.46 (1.3) 1.39 (1.3)
Enterococcus spp 4 (4) 1.5 (1.5) 1 (1) 1 (1) 1 (1)
Cataract surgery 3.06 (3) 0.96† 1.08 (0.6) 0.04† 0.74 (0.48) 0.002† 0.70 (0.48) 0.0009† 0.73 (0.48) 0.002†
Intravitreal injection 3.07 (3) 1.80 (2) 1.51 (1.3) 1.46 (1.3) 1.42 (1.3)
Other‡ 3.43 (4) 0.38 2 (2) 0.22 1.31 (1) 0.83 1.04 (0.77) 0.74 1.02 (0.7) 0.66
*Calculated using Student T test or analysis of variance, compared with baseline.
†Comparing cataract surgery with intravitreal injection. 
‡Other refers to trabeculectomy/intraocular lens exchange/vitrectomy/globe rupture/endogenous endophthalmitis; P values are compared with cataract 
surgery.
TABLE 3. Visual Acuity of Patients 1 Year Post Early Vitrectomy









All patients 16/64 (25) 27/64 (42) 32/64 (50) 15/64 (23)
Culture-positive 6/42 (14) 0.006 11/42 (26) 0.0005 15/42 (36) 0.003 12/42 (29) 0.23
Culture-negative 10/22 (45) 16/22 (73) 17/22 (77) 3/22 (14)
Gram-positive 6/39 (15) 0.46 11/39 (28) 0.55 15/39 (38) 0.25 10/39 (26) 0.19
Gram-negative 0 0 0 2/3 (67)
Staphylococcus epidermidis 6/18 (33) 0.04 10/18 (56) 0.002 12/18 (67) 0.001 4/18 (22) 0.25
Staphylococcus aureus 0 1/5 (20) 1/5 (20) 3/5 (60)
Streptococcus spp 0 0 1/14 (7) 3/14 (21)
Enterococcus spp 0 0 0 1/2 (50)
Cataract surgery 12/34 (35) 0.06 18/34 (53) 0.04 21/34 (62) 0.05 5/34 (15) 0.11
Intravitreal injection 3/23 (13) 6/23 (26) 8/23 (35) 8/23 (35)
Cataract surgery 12/34 (35) 0.37 18/34 (53) 0.99 21/34 (62) 0.67 5/34 (15) 0.28
Other† 1/6 (17) 3/6 (50) 3/6 (50) 2/6 (33) 
*Calculated using Chi square or Fisher exact test (if <5 counts in any cell).
†Other refers to trabeculectomy/intraocular lens exchange/vitrectomy/globe rupture/endogenous endophthalmitis.
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(P = 0.06). Similarly, post–cataract surgery patients had a greater 
likelihood of achieving a logMAR of +0.477 (P = 0.04) and 
+0.7 (P = 0.05) or better when compared with those who had 
intravitreal injections. 
Table 4 shows the results of the multivariate analyses. Only 
presenting VA and sex were independently associated with 
improvements in VA from baseline to 1 year. Patients with VA of 
LP or HM at presentation gained substantially more vision than 
those with CF. Men gained more vision than women at 1 year.
Intraoperative and postoperative complications were 
relatively common. Of 64 patients, 6 (9%) had intraoperative 
rhegmatogenous retinal detachment; 4 of them were diagnosed 
preoperatively with B-scan ultrasound. There were 4 patients 
(6%) who had retinal detachment postoperatively, occurring at a 
median time of 11 days (SD, 23; range, 7–56 days) after surgery. 
Two patients (3%) required an evisceration, of whom both had 
intraoperative retinal detachment. Six patients (9%) developed 
epiretinal membrane, 1 (2%) had postoperative hypotony and 
4 (6%) developed ocular hypertension. Of the latter 4 patients, 
3 still required topical hypotensive agents at the last follow-
up examination. Among the patients who developed retinal 
detachment, final VA at 1 year was 1.9 (slightly better than CF). 
All had silicone oil removed by that time. 
 
DISCUSSION
In this retrospective cohort study of patients who underwent 
early PPV for IE, a majority experienced some degree of 
visual recovery. A total of 89% of patients experienced visual 
improvement of 1 line or better while only 3% had worse vision 
at 1 year. Cataract surgery as the etiological cause and negative 
microbial cultures were positive prognostic factors, and in 
multivariable analyses patients with LP- or HM-baseline VA 
achieved more visual gains after early PPV than those with CF 
vision. 
There is controversy regarding the role of early PPV in 
treating IE.2,17–19 Chaudhary et al11 found that patients underwent 
tap and injection of intravitreal antibiotics alone regained baseline 
VA more often than those who underwent tap and injection with 
subsequent PPV (90% vs 46%). Kurniawan et al20 and Xu et al21 
have also reported no benefit of early PPV in improving visual 
outcomes. Population studies in the US and Australia have 
reported that PPV usage is higher than that recommended by the 
EVS, but with no evidence of increased benefit.3,22
In contrast, a number of case series have reported good 
outcomes following early PPV. Panarci et al23 reported 40% of 
their patients achieved final VA of 20/40, while other studies by 
Kuhn and Gini,4 Tan et al,24 and Almanjoumi et al25 have reported 
even higher percentages of 91%, 83.3%, and approximately 
80% achieving final VA of 20/40, respectively. Another 
retrospective study found only early PPV was associated with 
better visual outcome in streptococcal IE.26 Finally, surveys of 
ophthalmologists have found the majority perform early PPV 
if there is clinical worsening within 48 hours following tap and 
injection of antibiotics.27 In our study, 23% of patients achieved a 
final VA of 20/40 following early PPV, which is lower than that 
reported in other series (40%–91%).4,23–25 This may be due to the 
relatively high percentage of patients with preexisting poor visual 
potential due to macular degeneration and who were receiving 
intravitreal anti–vascular endothelial growth factor therapy in our 
study. 
We identified post–cataract surgery etiology and culture-
negative microbial growth as positive prognostic factors for 
better final VA. These factors have also been identified in other 
studies.28,29 Culture-positive cases may indicate more virulent 
bacteria as well as the presence of a greater intraocular bacterial 
load. Of those cases that were culture positive, S. epidermidis 
was associated with a better visual outcome compared with 
other pathogens, which has also been reported by others.28,29 In 
multivariable analyses adjusting for age, sex, culture, etiology, 
days from surgery and baseline vision, poorer baseline vision was 
most strongly associated with improvement in VA, with a weaker 
association of male sex. This suggests that while surgical etiology 
and culture results are predictive factors for VA improvement 
following early PPV, their prognostic value is captured in 
baseline VA measurements. This finding reveals the importance 
of measuring baseline VA and validates the EVS approach of 
determining treatment based on baseline vision.1 Further, we 
report that patients with baseline VA of LP or HM experienced 
similar visual gains, suggesting that early PPV may be beneficial 
not only for patients with presenting VA of LP (as shown by 
the EVS), but also for patients with HM vision. A randomized 
clinical trial of early PPV is warranted in this area. 
Strengths of this study include a moderately large sample 
size, inclusion of multiple etiologies including post–cataract 
surgery and intravitreal injections, recruitment from a single 
center with less variability in PPV protocols, and adjustment for 
predictive factors including baseline VA. Limitations include 
the retrospective nature of data collection and lack of a control 
TABLE 4. Multivariate Analyses of Variables Predicting the Change in 
Visual Acuity After Early Vitrectomy
Variable
Change (SD) in logMAR 
Visual Acuity*











Intravitreal injection −1.64 (1.04)
Other −2.48 (0.96)
Cataract surgery −2.29 (0.97)
Days from initial surgery 0.62
≤4 −2.23 (1.02)
>4 −1.85 (1.02)
Baseline visual acuity, logMAR <0.0001
+4.0 (light perception) −2.68 (0.91)
+3.0 (hand motion) −2.09 (0.84)
+2.0 (counting fingers) −0.85 (0.78)
*Adjusted for age, sex, culture, etiology, days from surgery, and 
baseline vision.
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group. We did not include a control group such as patients who 
received only a tap and injection of antibiotics as these patients 
have milder forms of IE with better prognosis, and comparison 
with the more severe patients with early PPV would introduce 
confounding by indication. This bias can only be fully dealt with 
in a randomized controlled trial setting. 
In conclusion, our study showed that a majority of patients 
with acute IE undergoing early PPV experience VA improvement. 
Endophthalmitis after cataract surgery and negative microbial 
cultures predicted better final visual outcome. After adjusting 
for these and other factors, patients with presenting VA of LP or 
HM achieved higher visual gains than those with CF, suggesting 
early PPV may be beneficial in patients with HM- as well as 
LP-baseline VA. Since the publication of the EVS, significant 
changes in the etiological causes and surgical management 
options for the treatment of acute IE have occurred, and the 
indications for early PPV may need to be re-examined, preferably 
in a new randomized clinical trial. 
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